Due to the specific affinity of the RS17 peptide for CD47 on tumor cells and the innate homing ability of the M1 EVs, REV@SR780Fe@LEV-RS17 NPs targeted tumors and accumulated at tumor sites after intravenous administration. This evidence concerns the gene CD47 and neoplasm.